Impending biologics patent expiries creates huge opportunity for European biosimilars makers

The biosimilars manufacturing industry is at a nascent stage. However, the impending patent expiries of biologics are anticipated to result in the introduction of several new biosimilars and provide impetus to market development.

New analysis from Frost & Sullivan, titled Analysis of European Biosimilars Market, finds that the market earned revenue of around $172.0 million in 2010 and estimates this to reach approximately $3.9 billion in 2017, increasing at a compound annual growth rate (CAGR) of 56.7% from 2010 to 2017. This study covers the existing biosimilars segments (erythropoietin, granulocyte colony stimulating factors and human growth hormones) and emerging biosimilars segments (monoclonal antibodies, insulin and interferon - alpha and beta).